keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/29922063/initiating-maintaining-long-acting-injectable-antipsychotics-in-schizophrenia-schizoaffective-or-bipolar-disorder-expert-consensus-survey-part-2
#1
Martha Sajatovic, Ruth Ross, Susan N Legacy, Matthew Byerly, John M Kane, Faith DiBiasi, Heather Fitzgerald, Christoph U Correll
Objective: The aim of this study was to provide recommendations on initiating and maintaining long-acting injectable antipsychotics (LAIs) in individuals with schizophrenia/schizoaffective or bipolar disorder. Methods: A 50-question survey comprising 916 response options was completed by 34 expert researchers and high prescribers with extensive LAI experience, rating relative appropriateness/importance on a 9-point scale. Consensus was determined using chi-square test of score distributions...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29880238/antipsychotic-treatment-of-very-late-onset-schizophrenia-like-psychosis-atlas-a-randomised-controlled-double-blind-trial
#2
Robert Howard, Elizabeth Cort, Rosie Bradley, Emma Harper, Linda Kelly, Peter Bentham, Craig Ritchie, Suzanne Reeves, Waleed Fawzi, Gill Livingston, Andrew Sommerlad, Sabu Oomman, Ejaz Nazir, Ramin Nilforooshan, Robert Barber, Chris Fox, Ajay Verma Macharouthu, Pranathi Ramachandra, Vivek Pattan, John Sykes, Val Curran, Cornelius Katona, Tom Dening, Martin Knapp, Richard Gray
BACKGROUND: Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks. METHODS: The ATLAS double-blind controlled trial enrolled participants from 25 old age psychiatry services in the UK...
June 4, 2018: Lancet Psychiatry
https://www.readbyqxmd.com/read/29862493/characteristics-of-depressive-and-bipolar-disorder-patients-with-mixed-features
#3
L Tondo, G H Vázquez, M Pinna, P A Vaccotto, R J Baldessarini
OBJECTIVE: To assess differences between subjects with vs. without mixed features in major affective disorders. METHODS: In 3099 out-patient subjects with DSM-5 major depressive disorder (MDD, n = 1921) or bipolar disorders (BD, n = 1178), we compared those with (Mx) vs. without (Non-Mx) mixed features (agitated-irritable depression or dysphoric [hypo]mania) in an index episode. RESULTS: Prevalence of Mx averaged 21.9% [CI: 20.5-23.4] overall, ranking: BD-II > BD-I > MDD, and in BD depression ≥ [hypo]mania > MDD...
June 3, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29859501/relationship-between-bipolar-disorder-and-attention-deficit-hyperkinetic-disorder-an-exploratory-study
#4
Soumya Jhanda, Savita Malhotra, Sandeep Grover
OBJECTIVES: This study aimed to evaluate the impact of comorbid attention deficit hyperkinetic disorder (ADHD) on Bipolar disorder (BD). METHODS: Patients aged 13-40 years with diagnosis of BD with ADHD (N = 30) were compared to those with BD without ADHD (N = 69) for clinical course, functional outcome and quality of life. RESULTS: Those with BD + ADHD had significantly lower age of onset of BD (p < 0.001), a significantly higher number of total lifetime episodes (p = 0...
May 19, 2018: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29790360/-current-and-future-pharmacotherapy-of-severe-psychiatric-disorders
#5
Eva Češková
Despite of tremendous development in CNS research, current treatment is suboptimal especially in severe mental disorders. In medicine, there are two main methods of improving the healthcare provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring, but also implementation of general trends into the clinical practice. New pharmacological options include drugs aimed at other than monoaminergic systems and old drugs used before the psychopharmacological era...
2018: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/29783976/possible-multiple-system-atrophy-with-predominant-parkinsonism-in-a-patient-with-chronic-schizophrenia-a-case-report
#6
Hiroshi Komatsu, Masaaki Kato, Teiko Kinpara, Takashi Ono, Yoshihisa Kakuto
BACKGROUND: Multiple system atrophy (MSA) is an adult-onset, rare, and progressive neurodegenerative disorder characterized by a varying combination of autonomic failure, cerebellar ataxia, and parkinsonism. MSA is categorized as MSA-P with predominant parkinsonism, and as MSA-C with predominant cerebellar features. The prevalence of MSA has been reported to be between 1.86 and 4.9 cases per 100,000 individuals. In contrast, approximately 1% of the population is affected by schizophrenia during their lifetime; therefore, MSA-P comorbidity is very rare in schizophrenic patients...
May 21, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29765242/claims-based-proxies-of-patient-instability-among-commercially-insured-adults-with-schizophrenia
#7
Charles Ruetsch, Hyong Un, Heidi C Waters
Objective: Schizophrenia (Sz) patients are among the highest utilizers of hospital-based services. Prevention of relapse is in part a treatment goal in order to reduce hospital admissions. However, predicting relapse is a challenge, particularly for payers and disease management firms with only access to claims data. Understandably, such organizations have had little success predicting relapse. A tool that allows payers to identify patients at elevated risk of relapse could facilitate targeted interventions prior to relapse and avoid rehospitalization...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29764266/impact-of-paliperidone-palmitate-one-month-formulation-on-relapse-prevention-in-patients-with-schizophrenia-a-post-hoc-analysis-of-a-one-year-open-label-study-stratified-by-medication-adherence
#8
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang, Yu Feng
BACKGROUND: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. AIM: The purpose of this study was to investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia...
May 1, 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29749607/increasing-antipsychotic-dose-versus-switching-antipsychotic-for-non-response-in-schizophrenia
#9
REVIEW
Myrto T Samara, Elisabeth Klupp, Bartosz Helfer, Philipp H Rothe, Johannes Schneider-Thoma, Stefan Leucht
BACKGROUND: Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug. OBJECTIVES: To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017)...
May 11, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29730876/qtc-prolongation-and-ventricular-trigemini-with-asenapine-a-case-report
#10
Jesjeet Singh Gıll, Ahmad Hatim Sulaıman
Asenapine is one of the newer atypical antipsychotics on the market. It is a sublingually administered drug that is indicated for the treatment of both schizophrenia and bipolar disorder, and is considered to be safe and well tolerated. Herein, we report a 71-year-old female with a history of bipolar disorder who had ventricular trigemini and experienced a large increase in her QTc interval after starting treatment with asenapine. These changes ceased following withdrawal of asenapine. In this case report, we discuss the importance of cardiac monitoring when switching antipsychotics, even to those that are considered to have low cardiac risk...
2018: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/29685069/the-assessment-and-treatment-of-antipsychotic-induced-akathisia
#11
Tamara Pringsheim, David Gardner, Donald Addington, Davide Martino, Francesca Morgante, Lucia Ricciardi, Norman Poole, Gary Remington, Mark Edwards, Alan Carson, Thomas R E Barnes
Akathisia is a common and distressing neuropsychiatric syndrome associated with antipsychotic medication, characterised by subjective and objective psychomotor restlessness. The goal of this guideline is to provide clinicians with recommendations on the assessment and treatment of akathisia. We performed a systematic review of therapeutic studies assessing the treatment of antipsychotic-induced extrapyramidal symptoms. Forty studies on akathisia and 4 systematic reviews evaluating the adverse effects of antipsychotics were used in the formulation of recommendations...
January 1, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/29618351/hospitalization-outcomes-in-patients-with-schizophrenia-after-switching-to-lurasidone-or-quetiapine-a-us-claims-database-analysis
#12
John W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebel
BACKGROUND: This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. METHODS: This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 2010 through December 2012) and MarketScan® Commercial Claims and Encounters Database (April 2010 through October 2013). Continuous enrollment for 6-months before and after medication initiation was required...
April 4, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29607408/therapeutic-effects-of-prolonged-cannabidiol-treatment-on-psychological-symptoms-and-cognitive-function-in-regular-cannabis-users-a-pragmatic-open-label-clinical-trial
#13
Nadia Solowij, Samantha J Broyd, Camilla Beale, Julie-Anne Prick, Lisa-Marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J Croft, Jennifer H Martin, Murat Yücel
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ9 -tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in a prolonged administration trial in otherwise healthy cannabis users...
2018: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/29606876/factors-related-to-improvement-of-symptoms-function-and-caregiver-burden-in-chinese-patients-with-schizophrenia-after-switching-to-paliperidone-palmitate-once-monthly-from-oral-antipsychotics
#14
Nan Li, Yu Feng, Huafei Lu, Shang Li Cai, Jianmin Zhuo, Tianmei Si, Lili Zhang
Background: Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and functional remission in patients with schizophrenia. This post hoc analysis aimed to identify factors associated with improved clinical outcomes in patients switching to PP1M (75-150 mg eq.). Methods: The improved patient outcomes were observed as Positive and Negative Symptom Scale (PANSS, symptoms) score <70:66.7% (407/610), Personal and Social Performance (PSP, function) score >70:34...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29602172/no-differences-in-olanzapine-and-risperidone-related-weight-gain-between-women-and-men-a-meta-analysis-of-short-and-middle-term-treatment
#15
G Schoretsanitis, M Drukker, J Van Os, K R J Schruers, M Bak
OBJECTIVE: A plethora of data deriving from single studies as well as meta-analyses demonstrates that weight gain is associated with the exposure to the majority of antipsychotics (AP). However, potential sex differences have widely evaded the attention of AP treatment trials. It is hypothesised that female patients gain more weight compared with male patients due to their enhanced susceptibility to adverse drug reactions. METHOD: A meta-analysis was conducted using clinical trials of AP that reported weight change separately for female and male patients...
March 30, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29582518/long-term-safety-and-effectiveness-of-brexpiprazole-in-japanese-patients-with-schizophrenia-a-52-week-open-label-study
#16
Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
AIM: This study assessed the long-term safety, tolerability, and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia. METHODS: This 52-week, open-label, flexible-dose (1-4 mg/day) study included patients with schizophrenia who continued treatment from a short-term randomized placebo-controlled fixed-dose (1, 2, or 4 mg/day) trial and de novo patients who switched from other antipsychotics. RESULTS: A total of 282 patients (184 de novo and 98 rolled over from short-term trial) entered the 52-week treatment with brexpiprazole, and 150 (53...
March 26, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29570965/can-aripiprazole-worsen-psychosis-in-schizophrenia-a-meta-analysis-of-double-blind-randomized-controlled-trials
#17
Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remington
BACKGROUND: Numerous case reports have reported psychotic worsening when switching to or adding aripiprazole in patients with schizophrenia. The risk of psychotic worsening related to aripiprazole was evaluated through a systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched using the following keywords: (schizophr* or schizoaff*) AND aripiprazole, with a limitation of randomized controlled trial and English language (last search: September 9, 2016) by the authors in an independent fashion...
March 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29568276/effects-of-continuing-oral-risperidone-vs-switching-from-risperidone-to-risperidone-long-acting-injection-on-cognitive-function-in-stable-schizophrenia-patients-a-pilot-study
#18
Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimura
Objectives: Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. Methods: Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group)...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29563800/efficacy-tolerability-and-safety-of-oral-paliperidone-extended-release-in-the-treatment-of-schizophrenia-a-24-week-open-label-prospective-switch-study-in-different-settings-in-taiwan
#19
Ching-Yen Chen, Tze-Chun Tang, Tzu-Ting Chen, Ya Mei Bai, Huei-Huang Tsai, Hou-Liang Chen, Chun-Jen Huang, Chih-Ken Chen, Chun-Chih Chen, Mei-Chun Hsiao, Chia-Yih Liu, Hong-Shiow Yeh, Nan-Ying Chiu, Cheng-Chen Hsiao, Cheng-Sheng Chen, Tung-Ping Su
Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists' judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29559781/novel-treatment-options-in-depression-and-psychosis
#20
REVIEW
Eva Ceskova, Petr Silhan
In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets...
2018: Neuropsychiatric Disease and Treatment
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"